Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Lucentis

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Lucentis was produced by Novartis and Roche.

Novartis stumbles in Q2 as COVID-19 impacts sales

Novartis stumbles in Q2 as COVID-19 impacts sales

That includes its wet AMD drug Lucentis (ranibizumab), which fell 25% to bring in $401m in the quarter.

Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD

Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD aflibercept) squaring off against Novartis’ older drug Lucentis (ranibizumab), the first VEGF inhibitor for wet AMD to reach the market. ... Novartis’ sales of Lucentis managed a slight gain overall in 2019 to just over $2bn, but fell slightly in the

Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture

Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture Lucentis was the first VEGF inhibitor to reach the market for wet AMD and grew quickly into a blockbuster product with sales of around $3.7bn last year. ... Alteogen and Momenta/Mylan have versions of Eylea in development, while Coherus and Xbrane Pharma

Novartis bags US okay for Lucentis follow-up Beovu in wet AMD

Novartis bags US okay for Lucentis follow-up Beovu in wet AMD The green light for Beovu (brolucizumab) is a boost for Novartis as it tries to defend its  wet AMD franchise, currently represented by $2bn-plus VEGF inhibitor product  Lucentis (ranibizumab) which ... That compares to four to eight week dosing with

Alcon spun off, leaner Novartis raises profit forecast

Alcon spun off, leaner Novartis raises profit forecast These include rare disease gene therapy Zolgensma, breast cancer candidate alpelisib (BYL719)  and Lucentis follow-up brolucizumab.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
certain health

Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...

Latest intelligence

PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
Sharing patient stories for World Pulmonary Hypertension Day
For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition. Created in collaboration with the PH patient...